California is currently home to 5930 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Recruiting
This is a prospective, multi-center, pilot feasibility study to document the effects of adventitial delivery of temsirolimus or temsirolimus with dexamethasone sodium phosphate injection, USP, after revascularization of femoropopliteal lesions in symptomatic patients with moderate to severe claudication (Rutherford 2-3) or critical limb ischemia (CLI) with rest pain (Rutherford 4). Subjects will be followed for up to 60 months post index procedure.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
08/31/2020
Locations: St. Joseph Hospital of Orange Heart and Vascular Center, Orange, California
Conditions: Peripheral Arterial Disease
Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia
Recruiting
To evaluate the efficacy and safety of cariprazine at a target dose of 4.5 mg/d compared with placebo in prevention of relapse in patients with schizophrenia To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/d compared with placebo in prevention of relapse in patients with schizophrenia who were initially stabilized on a target dose of 4.5 mg/d
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
08/17/2020
Locations: California Pharmaceutical Research Institute, Inc., Anaheim, California
Conditions: Schizophrenia
Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment
Recruiting
Cardiovascular disease (CVD) remains the leading cause of death in the United States, and improved CVD risk assessment is needed for personalized medicine. Atherosclerosis measures including plaque volume and adverse plaque features have prognostic value. Novel techniques have been developed for assessing carotid, coronary, and femoral atherosclerosis using magnetic resonance imaging (MRI) methods that are rapid and reproducible, have improved spatial resolution, and do not require contrast medi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/06/2020
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Cardiovascular Disease, Atherosclerosis
Inducing Graft Tolerance in HLA Haplotype Matched Related and 3 Ag Matched Unrelated Living Donor Kidney Transplantation
Recruiting
This research study is to determine if donor blood stem cells given after living, related, HLA antigen (Ag) haplotype match or living, unrelated donor kidney transplantation. Minimal HLA antigen matching will include matching of 2 HLA antigens that can be either HLA A, B, and /or DR. This research will change the immune system such that immunosuppressive drugs can be completely withdrawn or reduced to minimal dose without kidney rejection.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
07/15/2020
Locations: Stanford University Medical Center, Palo Alto, California
Conditions: Immune Tolerance
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.
Recruiting
This study T-Cell Project 2.0 is based on the former International PTCL study designed by the International T-cell Non-Hodgkin's Lymphoma Study Group (T-Cell Project 1.0: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma) as a prospective collection of data to predict the prognosis of patients with the more frequent subtypes of PTCL. It is a prospective, longitudinal, international, observational study of patients with newly diagnosed peripheral T-cell lymphoma aiming to... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/08/2020
Locations: Stanford University, Stanford, California
Conditions: Peripheral T-Cell Lymphoma
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML
Recruiting
A phase III randomized multi-center study designed to compare the efficacy of crenolanib with that of midostaurin when administered following induction chemotherapy, consolidation chemotherapy and bone marrow transplantation in newly diagnosed AML subjects with FLT3 mutation. About 510 subjects will be randomized in a 1:1 ratio to receive either crenolanib in addition to standard first line treatment of AML (chemotherapy and if eligible, transplantation) (arm A) or midostaurin and standard treat... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
05/21/2020
Locations: City of Hope National Medical Center, Duarte, California
Conditions: Newly Diagnosed FLT3 Mutated AML
Filter Initial & Long Term Evaluation After Placement and Retrieval Registry
Recruiting
A prospective data registry for all patients who undergo IVC (Inferior Vena Cava) filter placement or retrieval at Stanford. Potential enrollees will already be undergoing the procedure. If patients are willing, they will be prospectively enrolled prior to the procedure. As part of the study, chart and clinical data reviews will be used to track patient progress and response to the treatment.
Gender:
All
Ages:
All
Trial Updated:
05/09/2020
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Venous Thromboembolism
Epigenetic Regulation of Altered T-cell Immunity in Sarcoidosis
Recruiting
Sarcoidosis is a multi-system granulomatous disorder that is triggered and influenced by gene-environment interactions. Although sarcoidosis predominantly affects the lungs in most cases, the clinical disease course is highly variable and any organ can be affected leading to end organ damage despite currently available therapeutics that unfortunately also have numerous and potentially devastating side effects. The environmental triggers of sarcoidosis are unknown but several occupational, enviro... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
05/04/2020
Locations: University of California, San Francisco (Parnassus), San Francisco, California
Conditions: Sarcoidosis, Sarcoidosis, Pulmonary
Biocellular-Cellular Regenerative Treatment Scaring Alopecia and Alopecia Areata
Recruiting
The primary objective of this study is to evaluate the safety and efficacy of the use of a biocellular mixture of emulsified adipose-derived tissue stromal vascular fraction (AD-tSVF) and high density platelet-rich plasma concentrate (HD- PRP). Additionally, comparison with clinical outcomes of adipose-derived cellular Stromal Vascular Fraction (AD-cSVF) + AD-tSVF + HD PRP; AD-cSVF + emulsified AD-tSVF + HD- PRP; emulsified AD-tSVF + HD PRP + AD-cSVF; AD-cSVF via intravenous infusion in treatmen... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/15/2020
Locations: Kenneth Williams, DO, Irvine, California
Conditions: Alopecia Areata, Scarring Alopecia
Gentamicin for Junctional Epidermolysis Bullosa
Recruiting
Herlitz junctional epidermolysis bullosa (H-JEB), an incurable, fatal, inherited skin disease, is caused by loss-of-function mutations in the LAMA3, LAMB3 or LAMC2 genes, resulting in loss of laminin 332 and poor epidermal-dermal adherence. Eighty percent of H-JEB patients have LAMB3 mutations and about 95% of these are nonsense mutations. The investigators recently demonstrated that gentamicin readily induced nonsense mutation readthrough and produced full-length laminin beta3 in several nonsen... Read More
Gender:
All
Ages:
All
Trial Updated:
04/03/2020
Locations: University of Southern California, Los Angeles, California
Conditions: Junctional Epidermolysis Bullosa
Antibiotic Prophylaxis With Routine Ureteral Stent Removal
Recruiting
This study will be a single-institutional randomized, single-blinded prospectively controlled clinical trial of a single dose of Ciprofloxicin 500mg antibiotic tablet as prophylaxis at the time of office flexible cystoscopy with ureteral stent removal. The control group will be no prophylaxis oral antibiotics.
Gender:
All
Ages:
All
Trial Updated:
03/23/2020
Locations: University of California, San Diego, San Diego, California
Conditions: Urolithiasis, UTI
Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2
Recruiting
This study will be a multi-institutional randomized clinical trial of a short course of pre-operative antibiotic prophylaxis in addition to perioperative antibiotics prior to undergoing percutaneous nephrolithotomy. The select patient population will be those patients deemed to be at a moderately increased risk of postoperative infectious complications. These higher risk patients are those with indwelling urinary drainage tubes and those with a positive preoperative urine culture.
Gender:
All
Ages:
All
Trial Updated:
03/23/2020
Locations: University of California San Diego, San Diego, California
Conditions: Nephrolithiasis, Urinary Tract Infection (UTI), Sepsis